Investors Are Invited to Lead Soleno Therapeutics Inc. Securities Fraud Case

Overview of the Legal Situation

In a significant legal development, investors are being called to action regarding Soleno Therapeutics, Inc. This announcement comes from the Schall Law Firm, a prominent national entity in shareholder rights litigation. They are currently leading the charge against Soleno Therapeutics through a class action lawsuit alleging serious violations of the Securities Exchange Act of 1934. This suit is particularly aimed at addressing claims under sections 10(b) and 20(a), alongside Rule 10b-5 established by the U.S. Securities and Exchange Commission (SEC). This legal action emphasizes the importance of vigilance among investors.

Key Details of the Lawsuit

The class action is centered around a specific timeframe, urging all investors who purchased Soleno's securities from March 26, 2025, to November 4, 2025, to come forward. These investors have until May 5, 2026, to express their interest in joining the lawsuit. The core of the lawsuit is based on accusations that Soleno provided the market with misleading statements regarding the safety and efficacy of their product, particularly the diazoxide choline extended-release tablets (DCCR).

Allegations Against Soleno Therapeutics

According to the complaint, Soleno Therapeutics downplayed the safety concerns highlighted during their Phase 3 clinical trials. Reports suggest that the DCCR treatment involved serious risks that were not disclosed adequately to investors. Furthermore, the commercial viability of the treatment was significantly overstated, potentially exposing investors to risks associated with undisclosed adverse events. As investors discovered these truths, losses mounted, which solidified the basis for this class action.

How Investors Can Participate

For those who believe they have experienced losses due to these misleading practices, the Schall Law Firm is encouraging victims to come forward. Investors can join the class action by reaching out to Brian Schall at the firm’s office located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067. There is no cost to discuss the matter initially, and all inquiries can be directed to the firm's website or via email at [email protected].

What’s Next?

Currently, the class has not yet been certified. Until this process is completed, investors are not represented by an attorney in this case unless they take action to join the lawsuit. Those choosing to remain passive will be classified as absent from the class. The Schall Law Firm is committed to advocating for the rights of shareholders and aims to recover losses incurred by investors stemming from Soleno’s alleged deceitful public statements.

Conclusion

The implications of this case extend beyond those directly hurt financially; they encapsulate the broader narrative of corporate accountability within the biotech space. This ongoing litigation serves as a crucial reminder for investors to remain informed and proactive regarding their investments, particularly when faced with potential securities fraud. For those affected, joining the Schall Law Firm's class action might not only represent a chance for recovering losses but also a stand for investor rights in the face of corporate misconduct.